Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | Aciont® to Present at the 13th Annual NIH SBIR/STTR ConferenceDr. Kongnara Papangkorn’s presentation is entitled,“Safety Aspects and Drug Delivery Performance of Visulex® Passive Delivery System”
By: Aciont Inc Dr. Papangkorn’s abstract, entitled, “Safety Aspects and Drug Delivery Performance of Visulex® Passive Delivery System,” will take place on June 22, 2011 from 2:45 – 3:45 pm during the poster session on the atrium level of the Conference Center. Over fifty NIH SBIR/STTR Phase II awardees will display their scientific findings during the poster session to over 400 conference attendees. Information about the conference can be found at http://grants.nih.gov/ “We are thankful for the support of the NEI, and are very excited to share our latest results with the agency and other attendees on the NIH campus,” stated Dr. Papangkorn. “Our preclinical data appear to indicate that our DSP Visulex system is safe and performs well in terms of treating a preclinical uveitis model and delivering therapeutically relevant amounts of steroid drug to both the front and back of the eye in a rabbit model,” said Balbir Brar, Ph.D., D.V.M., Aciont’s Vice President of Research and Development. “Much of the data will be used to support our IND filing,” Brar added. --- Aciont Inc. is a specialty biopharmaceutical company endeavoring to become the world leader in commercializing localized, non-invasive (topical passive diffusion-based and iontophoretic) Source: Aciont Inc. Contact John Higuchi, CEO Aciont, Inc. (801) 359-3461 admin@aciont.com End
Account Email Address Disclaimer Report Abuse
|
|